You are here

Generic Version of Zoloft Receives Tentative Approval

FORT LEE, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE:ALO) , a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted tentative approval for the company's ANDA for sertraline hydrochloride 25 mg, 50 mg, and 100 mg tablets. Alpharma's sertraline hydrochloride tablets are the AB-rated generic equivalent of Pfizer's Zoloft(R) tablets, a product indicated for several disorders, including depression. Zoloft(R) tablet sales in 2004 were approximately $3 billion.

This tentative approval was received by the company's U.S. Generic business. On October 17, 2005, the company announced that it had reached a definitive agreement to sell both its U.S. and International Generics businesses to Actavis Group.

Source: Alpharma, Inc.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market